Since the sequencing of the human genome, genomics has been the buzzword in diagnostics. While some feel that it hasn't perhaps lived up to its promise, genomics is making its way into diagnostics, both in treatment and in preventive medicine.
Cancer research has brought forth many genetic biomarkers, and some have made it into practical everyday use, whereas others are still just interesting research findings. Despite only being founded in 2010, Foundation Medicine already has a genomics-based diagnostic tool on the market.
The FoundationOne molecular diagnostic test combines genetic sequencing, clinical information, and data gathering to help oncologists select the right drugs for their patients, based on mutations in 200 cancer-related genes.
Foundation Medicine made the Fierce 15 this year, and has raised $42.5 million in Series B funding this year. It has also attracted the attention of some major biopharma and life sciences companies, including partnerships and collaborations with Celgene ($CELG), Novartis ($NVS), Sanofi ($SNY), Clovis Oncology ($CLVS), Array BioPharma and Johnson & Johnson ($JNJ) Pharmaceutical Research and Development, among others.